Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Prospective, Randomized, Double-Blind, Placebo- Controlled, Single-Dose, Multicenter, Safety Study of FX-322 Administered by Intratympanic Injection in Adults With Severe Sensorineural Hearing Loss

NCT04629664 is registered in ClinicalTrials.gov with Frequency Therapeutics as lead sponsor.

NCT NCT04629664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04629664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Prospective, Randomized, Double-Blind, Placebo- Controlled, Single-Dose, Multicenter, Safety Study of FX-322 Administered by Intratympanic Injection in Adults With Severe Sensorineural Hearing Loss
Lead sponsor
Frequency Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
November 2, 2020
Completion date
September 20, 2021
Enrollment
31 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hearing loss, sensorineural, noise induced hearing loss, sudden hearing loss